The EBITDA math on payments: why basis points become enterprise value

If you run finance at a sponsor-backed business, you already think in multiples. Everyone else in the building thinks in dollars; you think in dollars times the number a buyer will pay for them. That lens changes how the payments line should be valued, because payments improvements are almost pure EBITDA, and EBITDA at exit carries a multiple.

The arithmetic

Every dollar you take out of processing cost drops to EBITDA. Every point of net collection you recover, net of the cost to recover it, drops to EBITDA. There is very little that sits between a payments improvement and the bottom line, which is what makes it different from most operational projects that consume cost as they create value.

Now apply the multiple. If the business trades at, say, twelve to fifteen times EBITDA, then a million dollars of recovered annual margin is not a million dollars. It is twelve to fifteen million of enterprise value, created before the event and captured by the existing owners. That is the entire reason payments is worth a CFO’s attention ahead of a process: the leverage is not the savings, it is the savings times the multiple.

Why payments specifically

Three properties make the payments line unusually clean:

It is recurring. Processing cost and collection performance repeat every month. A buyer underwriting the business capitalizes the run-rate, not a one-time gain, so the improvement is valued at the multiple rather than discounted as a non-recurring item.

It is defensible in diligence. A lower effective rate and a higher net collection rate are verifiable from the data. A quality-of-earnings team can confirm them, which means the improvement survives the scrutiny that haircuts softer add-backs.

It does not require disruption. You are not reorganizing the company or ripping out the EHR. The processing layer behind the bill is swappable, the rate is re-biddable, and the patient-pay and financing tooling layers on top. Low-risk improvements that survive diligence are exactly the kind a buyer pays full multiple for.

The trap to avoid

The wrong way to pitch this internally or to a board is “cheaper processing.” That frames it as procurement and caps the perceived value at the savings. The right frame is enterprise value: here is the recurring margin we recover, here is the multiple, here is what it adds to the equity value, and here is why it holds up when a buyer’s team looks closely. Same work, an order of magnitude different perceived worth.

Timing

The levers are cleaner before a process than during one. Recovered margin captured on your own clock is value you keep; the same leakage discovered by a buyer’s diligence team is a discount you absorb. The window to do this quietly and bank the multiple is while you still control the timeline.

This is the lens we bring to Healthcare & Revenue-Cycle Payments: not a rate quote, a quantified EBITDA and enterprise-value case. Start with the pre-screening questionnaire.